This review provides a comprehensive summary of the up-to-date published literature that validates the independent prognostic significance of pre-treatment, on-treatment, or post-treatment serum ALB level and various ALB-based mono- and combination biomarkers in predicting the prognosis of HCC patients undergoing different surgical, locoregional, and systemic treatments. The gene discussed is ALB; the disease is hepatocellular carcinoma.